Drug Trial Radar · NCT06245941
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
Last checked: Nov 19, 2026Latest source record: Jan 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
21
Actual
Start
May 13, 2024
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 tablets combined with TQB3909 tablets in patients with moderate- and high-risk Myelofibrosis.
Conditions
- Myelofibrosis
Interventions
TQ05105 tabletsDrug
TQ05105 is a Janus kinase 1 (JAK1) and Janus kinase 2 (JAK2) Inhibitor
TQB3909 tabletsDrug
TQB3909 is an inhibitor targeting B-cell lymphoma-2 (BCL-2) protein.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximal tolerance dose (MTD)Time frame: Up to 2 years.
- Recommended phase II dose (RP2D)Time frame: Up to 2 years
- 35% reduction in spleen volume (SVR35) at week 24Time frame: Up to 24 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
The Second People's Hospital of Hefei
Hefei, Anhui, China
Hennan Cancer Hospital
Zhengzhou, Henan, China
Xijing Hospital of the Fourth Military Medical University
Xi'an, Shaanxi, China
People's Hospital of Tianjin
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital Zhejiang University School Of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.